OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?

Ítems similars

• OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?
  per: Keith C. Ferdinand, et al.
  Publicat: (2024-10-01)
• Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays
  per: Gavin T. Buckley, et al.
  Publicat: (2024-09-01)
• Asundexian: a systematic review of safety, efficacy, and pharmacological insights in thrombosis
  per: Ziad Sad Aldeen, et al.
  Publicat: (2025-11-01)
• Impact of asundexian on a panel of coagulation assays
  per: Julie Vassart, et al.
  Publicat: (2025-07-01)
• Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources
  per: Alexander Hartenstein, et al.
  Publicat: (2023-10-01)